close

For more than four decades, Fenwick & West LLP has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.  MORE >

Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.  MORE >

From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.  MORE >

At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.  MORE >

Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:

  • Nearly 15 percent of Fenwick partners named America's Leading Lawyers for Business by Chambers USA and Chambers Global
  • Selected as a "Go-To" law firm by in-house legal departments at Fortune 500 companies in Corporate Counsel magazine
  • Named to The National Law Journal's inaugural "Intellectual Property Hot List" for outstanding patent, copyright, trademark and IP litigation services

MORE >

We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.  MORE >

At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.   MORE >

Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041
650.988.8500

San Francisco Office
555 California Street
12th Floor
San Francisco, CA 94104
415.875.2300

Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101
206.389.4510

Shanghai Office
36/F, Room 3690, Tower 2
Shanghai IFC
8 Century Avenue, Pudong
Shanghai 200120, China
+86 21 6062 6104

David Tellekson

Partner, Litigation

icon partner 206.389.4560  

Office: Seattle

中文

David Tellekson focuses his practice on litigating patent cases for clients in the areas of biotechnology, pharmaceuticals, polymer chemistry and medical devices. In addition to his trial work, he also consults on patent strategy, opinions and due diligence.

David is a frequent writer and lecturer in areas of patent law and patent litigation. He has been selected as a Washington "Super Lawyer" in the area of Intellectual Property Litigation each year since 2008. He has also been recognized as one of the top Intellectual Property Litigation lawyers in Washington by Chambers USA. In 2012, Intellectual Asset Management magazine named David to the IAM Patent 1000: The World’s Leading Patent Practitioners. Prior to joining Fenwick & West, he was the managing principal at Darby & Darby P.C. in Seattle.

Representative Engagements

  • Novozymes v. Danisco: Lead trial counsel representing Novozymes in a successful action against rival Danisco for infringement of Novozymes’ patent for an improved alpha-amylase useful for fuel ethanol production, among other industrial applications. A jury found that Danisco willfully infringed Novozymes’ patent and awarded over $18.2 million in damages.
  • Schering v. Glenmark: Lead counsel representing defendant Glenmark, the only challenger to Schering’s ezetimibe patent covering $5 billion per year drug. Favorable settlement on the eve of trial followed a Glenmark summary judgment victory.
  • Sigma-Aldrich and Oxford Biomedica (UK) Ltd. v. Open Biosystems: Represented patent owner Oxford Biomedica as lead trial counsel in patent infringement action involving HIV vectors useful for drug delivery. Markman victory led to favorable settlement.
  • Novozymes v. Genencor: Represented Novozymes as lead trial counsel asserting patent on genetically modified alpha-amylases. Genencor was found to willfully infringe and ordered to pay double damages and attorneys’ fees.
  • Cardiac Science v. Philips Electronics: Represented plaintiff as lead trial counsel in case involving 21 patents. Damages asserted by each side combined in excess of $200 million. Key victories by Cardiac Science at Markman and summary judgment led to favorable settlement hours before seven-week trial set to begin.
  • 3M v. Seibu Polymer Chemical Co., Ltd. (ITC): Co-trial counsel at patent infringement trial protecting retroreflective sheeting market valued at more than $1 billion per year.

Publications

  • David K. Tellekson and John LaBarre, The Intersection of Antitrust and Intellectual Property: A Review of Recent Case Law and Trends, BNA's Patent, Trademark & Copyright Journal, August 11, 2006.
  • David K. Tellekson, Sandra S. Lee and Elizabeth A. Richardson, Strategies for Attacking and Defending Pharmaceuticals Patents; A Modern Take on 'The Art of War,' Intellectual Property & Technology Law, December 2005.
  • David K. Tellekson and Elizabeth Bernard, Have Patent, Will Travel: Can One Infringe a U.S. Patent by Making, Using, and Selling a Product Solely Outside the United States?, Intellectual Property Today, July 2004.

Presentation

  • The Decline of Process Patents: Enforceability of process claims and the controversy around divided infringement, BIO IP Counsels Committee Conference, April 2012.

 

 

 
 

About David